Ensysce Biosciences have been selected to present one of the top 12 best Flash Talks in the Trailblazer Session at the 2024 American Association of Pain Medicine Meeting on March 9th. Dr. William Schmidt, Chief Medical Officer of Ensysce, will present “Preventing Prescription Drug Overdoses: Clinical development of Trypsin-Activated Abuse Deterrent Opioids with Overdose Protection”.The flash talk designation is awarded to a small number of programs that convey novel information with great potential and are of interest to pain specialists. Ensysce’s novel PF614-MPAR is designed to provide optimal pain relief at prescribed doses yet limit accidental or intentional overdose by ‘shutting down’ opioid release if too much active drug is consumed. PF614-MPAR could herald a new class of treatment for the most severe forms of pain and could save lives if approved, as each capsule contains built-in protection against both abuse and overdose which plague traditional opioids. In late January, the Company’s PF614-MPAR was granted Breakthrough Therapy designation by the FDA, recognizing its innovative approach to preventing prescription opioid overdoses. Dr. Lynn Kirkpatrick, PhD, Chief Executive Officer of Ensysce Biosciences, commented, “We are delighted to be recognized by AAPM, an organization which we hold in very high regard. We believe PF614-MPAR is a true game-changer but it’s always encouraging to learn that leading external experts share our enthusiasm. Following our constructive End of Phase 2 meeting with the FDA informing the strategic design of the upcoming Phase 3 studies, and recent Breakthrough Therapy Designation of PF614-MPAR, we are encouraged by the AAPM’s interest as we accelerate the development of the ‘Next Generation’ opioid to treat severe pain layered with overdose protective properties.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ENSC:
- Ensysce Biosciences completes End of Phase 2 meeting with FDA on PF614
- Ensysce Biosciences to present on PF614-MPAR at NIH HEAL Meeting
- Ensysce Biosciences announces Breakthrough Therapy Designation for PF614-MPAR
- Ensysce Biosciences files to sell common stock, warrants, no amount given
- Ensysce Biosciences CEO says 2024 ‘will be a pivotal year’ for the company